Milestone Scientific Inc. (MLSS)

In August 2025, Eric C. Hines was appointed as the new CEO. The company's Q3 2025 earnings reported an EPS loss of -$0.01, meeting estimates and triggering a 5.21% premarket stock surge, with revenue at $2.36 million, exceeding forecasts. In October 2025, Milestone Scientific provided a business update, highlighting strategic actions under the new CEO, including operating expense reductions of approximately 20% compared to Q3 2024 and an uptick in recurring revenue from CompuFlo disposables. As of February 6, 2026, the share price was $0.26, reflecting a -6.23% decrease from the prior week, and over the past year, the stock price has fluctuated between $0.22 and $1.28.

Explicit information regarding demand seasonality for Milestone Scientific's products and services is not detailed in the provided search results. However, the company's strategic shift to an e-commerce sales model for its dental division and the reported 43% year-over-year growth in domestic dental sales upon its implementation in Q1 2023 suggest efforts to potentially mitigate traditional seasonal fluctuations or capitalize on consistent demand. The growth in the medical segment is heavily tied to securing and expanding Medicare and commercial reimbursement, which may not inherently exhibit strong seasonality.

Milestone Scientific, Inc. is a biomedical technology company specializing in computer-controlled injection systems for medical and dental applications, aiming to enhance precision, efficiency, and safety. The company operates within the medical technology sector, specifically in the medical instruments and supplies industry, and its product lines are based on its proprietary Dynamic Pressure Sensing Technology®. Its major products include The Wand®, a computer-controlled system for local anesthesia delivery in dental procedures, and the CompuFlo® Epidural System, designed to enhance epidural procedures by providing real-time confirmation of epidural space entry. The company also offers CathCheck®, which provides real-time data for catheter placement during epidural procedures. These technologies are also being explored for applications in cosmetic botulinum toxin injections and intra-articular joint injections.

Milestone Scientific has a global market presence through partnerships with dental and medical device distributors and manufacturers. Its dental devices are sold in the United States, Canada, and over 41 other countries. The company has CE mark approval for certain medical devices, allowing them to be marketed and sold in various European countries. The company reported no revenue from China in Q3 2024.

Milestone Scientific has focused on enhancing its reputation through technological advancements and strategic market penetration. A significant positive event was receiving Medicare Part B physician payment rate assignment for its CompuFlo Epidural System across multiple Jurisdiction Medicare Administrative Contractors (JMACs). The appointment of Eric Hines as CEO in August 2025, with his emphasis on a more focused sales approach and streamlining digital marketing, aims to strengthen the company's competitive position and brand awareness. The current strategic initiatives are designed to address past shortcomings in sales leadership and improve overall operational efficiency.

Milestone Scientific Inc. has 42 institutional owners and shareholders, including Vanguard Group Inc., VTSMX, VEXMX, Geode Capital Management, Llc, FSMAX, BRUSX, BRSIX, State Street Corp, Susquehanna International Group, Llp, and Mariner, LLC. Individual owners with significant stakes include Gian Domenico Trombetta, Innovest SpA, Leonard Osser, and Neal Goldman. As of November 2025, retail and public float hold 83.45% of shares, insiders hold 10.88%, and institutional investors hold 5.67%.